Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Finance office Nick Luff (pictured) expects further growth after 2024 profit rose from £2.3bn to £2.6bn. Relx hiked its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback